Overview
Clinical Meaning
The clinician managing TAA must understand the genetics of heritable thoracic aortic disease, evidence based surgical thresholds, and long term post surgical surveillance.
The clinician managing TAA must understand the genetics of heritable thoracic aortic disease, evidence-based surgical thresholds, and long-term post-surgical surveillance. Heritable thoracic aortic disease (HTAD) accounts for approximately 20% of all TAAs and has specific clinical implications. Marfan syndrome (FBN1 mutation, prevalence 1:5000): fibrillin-1 deficiency causes increased TGF-beta signaling leading to aortic root dilation (80% of patients), lens subluxation, skeletal manifestations (tall stature, arachnodactyly, pectus deformity), and dural ectasia. Loeys-Dietz syndrome (TGFBR1/2, SMAD3, TGFB2/3 mutations): aggressive arterial disease with aneurysms throughout the arterial tree, arterial tortuosity, hypertelorism, bifid uvula, skin translucency; surgical threshold is lower (4.0-4.5 cm) due to higher rupture/dissection risk at smaller sizes. Vascular Ehlers-Danlos (vEDS, COL3A1 mutation): type III collagen deficiency causing extreme arterial fragility; spontaneous arterial rupture, bowel perforation, organ rupture; surgical intervention carries very high complication risk; avoid invasive vascular procedures when possible. Familial thoracic aortic aneurysm/dissection (FTAAD, ACTA2, MYH11 mutations): autosomal dominant without systemic features; ACTA2 mutations associated with early-onset stroke, coronary disease, livedo reticularis, and iris flocculi. The clinician coordinates genetic testing and counseling, applies genotype-specific surgical thresholds, and manages long-term surveillance.
